Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics Inc
(NQ:
IOVA
)
11.66
+0.28 (+2.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Iovance Biotherapeutics Inc
< Previous
1
2
3
Next >
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
November 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 20, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
October 16, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
October 10, 2023
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant...
Via
PressReach
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
Four-year Analysis of C-144-01 Trial Cohorts 2 and 4
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 22, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) is One of Friday Morning’s Most Active Stocks
September 15, 2023
Via
Investor Brand Network
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
September 14, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
September 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 18, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
August 08, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
July 25, 2023
Oral Presentation of Cohort 3A Data from IOV-COM-202 Phase 2 Clinical Trial of LN-145 in Combination with Pembrolizumab in Anti-PD1-naïve Advanced (metastatic or unresectable) Non-Small Cell Lung...
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
July 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 21, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
July 13, 2023
Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million Shares of Common Stock
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
June 20, 2023
Investor Conference Call and Webcast on June 26 at 5:00 p.m. ET
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
How to Trade Stocks Online the Right Way
June 13, 2023
Learning how active trading works requires serious education, including learning how to get started. Learn how to trade stocks online on MarketBeat.
Via
MarketBeat
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
June 09, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
May 30, 2023
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
Via
MarketBeat
Topics
Death
Exposures
Death
Product Safety
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
May 26, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 09, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
May 02, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
April 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
March 24, 2023
First TIL Therapy BLA Submission to U.S. Food and Drug Administration
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.